Our results further support the notion that KMT2D may play a role in metabolism and that KMT2DLOF alterations in STAD cases may also confer a vulnerability to OXPHOS or glycolytic perturbations. The gene discussed is KMT2D; the disease is gastric adenocarcinoma.